{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:31:28Z","timestamp":1778848288214,"version":"3.51.4"},"reference-count":42,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s251865","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T23:30:31Z","timestamp":1620603031000},"page":"1955-1963","source":"Crossref","is-referenced-by-count":21,"title":["Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Anandita","family":"Agarwala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Quispe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne C","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5084","authenticated-orcid":true,"given":"Erin D","family":"Michos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1161\/CIRCULATIONAHA.120.046961","volume":"141","author":"Khera","year":"2020","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMra1806939","volume":"381","author":"Michos","year":"2019","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1161\/CIR.0000000000000624","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/clc.22713","volume":"40","author":"Baum","year":"2017","journal-title":"Clin Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1161\/CIRCULATIONAHA.117.027705","volume":"135","author":"Knowles","year":"2017","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1042\/bj2720181","volume":"272","author":"Berkhout","year":"1990","journal-title":"Biochem J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1042\/bj3340113","volume":"334","author":"Pearce","year":"1998","journal-title":"Biochem J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","volume":"30","author":"Burke","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","volume":"45","author":"Cramer","year":"2004","journal-title":"J Lipid Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"E955","DOI":"10.1152\/ajpendo.90599.2008","volume":"296","author":"Jeong","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref16","unstructured":"A Multiple Ascending Dose Study of ETC-1002 in healthy subjects; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01485146. Accessed July 9, 2019."},{"key":"ref17","unstructured":"A Multiple Ascending Dose Study of ETC-1002 in subjects with mild dyslipidemia; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01105598. Accessed July 9, 2019."},{"key":"ref18","unstructured":"Single radiolabeled dose study to investigate the absorption, metabolism and excretion of [14C]-ETC-1002. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02044627. Accessed July 9, 2019."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"ref23","unstructured":"A study of the safety, pharmacokinetic drug interaction and efficacy of ETC-1002 and atorvastatin in subjects with hypercholesterolemia. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01779453. Accessed July 17, 2019."},{"key":"ref24","unstructured":"Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02178098. Accessed July 17, 2019."},{"key":"ref25","unstructured":"Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg when added to PCSK9 inhibitor therapy. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03193047. Accessed July 17, 2019."},{"key":"ref26","unstructured":"Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20 mg triplet therapy in patients with elevated LDL-C. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03051100. Accessed July 17, 2019."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Duell PB, Banach M, Catapano AL, Laufs U, Mancini GBJ, Ray KK, Bloedon LT, Ye Z and Goldberg AC. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials.\u00a0Atherosclerosis. 2020;315:e12\u2013e13 [abstract].","DOI":"10.1016\/j.atherosclerosis.2020.10.050"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1177\/2047487319864672","volume":"27","author":"Khan","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"ref36","unstructured":"Food and Drug Administration. NEXLETOL (bempedoic acid) prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211616s000lbl.pdf. Accessed December 29, 2020."},{"key":"ref37","unstructured":"Food and Drug Administration. Highlights of prescribing information NEXLIZET (bempedoic acid and ezetimibe) tablets, for oral use. Available from: https:\/\/www.accessdata.fdagov\/drugsatfda_docs\/label\/2020\/211617s000lbl.pdf. Accessed December 29, 2020."},{"key":"ref38","unstructured":"Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR outcomes). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993406. Accessed July 17, 2019."},{"key":"ref39","unstructured":"Esperion completes patient enrollment in the global CLEAR cardiovascular outcomes trialfor bempedoic acid; 2019. Available from: https:\/\/www.esperion.com\/investors-media\/press-releases\/. Accessed March 13, 2021."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","volume":"72","author":"Ference","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69230","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T23:30:43Z","timestamp":1620603043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/bempedoic-acid-for-heterozygous-familial-hypercholesterolemia-from-ben-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":42,"URL":"https:\/\/doi.org\/10.2147\/dddt.s251865","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}